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Summary
Background—The perinatal period is a time of high risk for onset of depressive disorders and is 
associated with substantial morbidity and mortality, including maternal suicide. Perinatal 
depression comprises a heterogeneous group of clinical subtypes, and further refinement is needed 
to improve treatment outcomes. We sought to empirically identify and describe clinically relevant 
phenotypic subtypes of perinatal depression, and further characterise subtypes by time of symptom 
onset within pregnancy and three post-partum periods.
Methods—Data were assembled from a subset of seven of 19 international sites in the 
Postpartum Depression: Action Towards Causes and Treatment (PACT) Consortium. In this 
analysis, the cohort was restricted to women aged 19–40 years with information about onset of 
depressive symptoms in the perinatal period and complete prospective data for the ten-item 
Edinburgh postnatal depression scale (EPDS). Principal components and common factor analysis 
were used to identify symptom dimensions in the EPDS. The National Institute of Mental Health 
research domain criteria functional constructs of negative valence and arousal were applied to the 
EPDS dimensions that reflect states of depressed mood, anhedonia, and anxiety. We used k-means 
clustering to identify subtypes of women sharing symptom patterns. Univariate and bivariate 
statistics were used to describe the subtypes.
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Findings—Data for 663 women were included in these analyses. We found evidence for three 
underlying dimensions measured by the EPDS: depressed mood, anxiety, and anhedonia. On the 
basis of these dimensions, we identified five distinct subtypes of perinatal depression: severe 
anxious depression, moderate anxious depression, anxious anhedonia, pure anhedonia, and 
resolved depression. These subtypes have clear differences in symptom quality and time of onset. 
Anxiety and anhedonia emerged as prominent symptom dimensions with post-partum onset and 
were notably severe.
Interpretation—Our findings show that there might be different types and severity of perinatal 
depression with varying time of onset throughout pregnancy and post partum. These findings 
support the need for tailored treatments that improve outcomes for women with perinatal 
depression.
Funding—Janssen Research & Development.
Introduction
In recent decades, a robust literature has documented the perinatal period as a time of high 
risk for onset of depressive disorders with substantial morbidity for mother, infant, and 
family that includes increased risk for low birthweight and prematurity, impaired mother-
infant attachment, and infant malnutrition during the first year of life.12 Maternal suicide is a 
leading cause of maternal mortality.3 Perinatal depression, broadly defined by WHO as onset 
of a major depressive episode during pregnancy or the first 12 months post partum, has a 
lifetime prevalence of 10–15% in developed countries2 and higher risk in low-income 
countries.4 The greatest point prevalence for onset of symptoms is the acute post-partum 
period,5 but there is growing evidence that many women have onset of symptoms during 
pregnancy.6 The public health importance of identifying women who have perinatal 
depression was highlighted by new recommendations of the US Preventive Services Task 
Force for screening for depression during pregnancy and post partum.7 These 
recommendations are consistent with guidelines from the National Institute for Health and 
Care Excellence (NICE) in the UK,8 the Australian Perinatal Depression Initiative,9 and 
WHO recommendations.10
An analysis of data from the international Postpartum Depression: Action Towards Causes 
and Treatment (PACT) Consortium, which represents 19 institutions in seven countries, 
showed substantial heterogeneity in symptoms of perinatal depression.11 This study used 
latent class analysis and described three specific latent classes (subtypes) of women with 
post-partum depression who differed by symptom severity, timing of onset (pregnancy vs 
post partum), history of previous mood or anxiety disorder, pregnancy or obstetric 
complications, and presence of suicidal ideation. These findings supported the need for 
further investigation to increase our understanding of the different phenotypes and type and 
quality of presentation associated with perinatal depression in women with onset during 
pregnancy versus post partum. These findings extended previous work documenting that 
comorbid anxiety is an important symptom in women with the most severe illness (eg, worry 
or ruminating thoughts).12 Additionally, these findings were consistent with results of a 
clinical trial that showed differential treatment response by the time of symptom onset in 
women with post-partum depression.13
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Anxiety and mood symptoms in perinatal depression have not been adequately described. 
We postulated that women who become depressed during pregnancy will differ in type and 
quality of presentation compared with those with post-partum onset. We wanted to examine 
this important issue in the PACT Consortium dataset, which had not been previously 
addressed in the first PACT study.11 We hypothesised that the underlying causes for onset 
and quality of symptoms across the perinatal period could be different on the basis of 
underlying pathophysiological mechanisms such as the hormonal fluctuations that 
characterise the perinatal period.14 Therefore, rather than focus on traditional diagnostic 
criteria for perinatal depression that do not account for co-occurring anxiety symptoms, we 
sought to examine the symptom constructs described in the National Institute of Mental 
Health (NIMH) research domain criteria (RDoC).15 The NIMH RDoC was developed to 
create a framework for research on pathophysiology that helps to inform future 
neuroscience-based diagnostic classification systems and ultimately leads to novel treatment 
and detection of subtypes for treatment selection.16 Application of the RDoC framework to 
examine the performance of mapping, screening, or diagnostic measures of depression to 
RDoC constructs has been an informative approach in other studies.17 We examined the 
RDoC functional constructs (ie, negative valence and arousal or regulatory systems)16 on the 
basis of patient report of symptoms assessed with the Edinburgh postnatal depression scale 
(EPDS) in the PACT Consortium.18 Examination of the EPDS factor structure has been 
described in the literature with consistent reports of subscales measuring mood and anxiety.
19
 A few studies have also described a potential third EPDS subscale for anhedonia20 or 
suicidal thoughts.21 We focused on the RDoC functional constructs of negative valence 
(anxiety) and arousal because the symptom of anxiety is often a hallmark phenotypic feature 
of the perinatal period.
The primary objective of our study was to empirically identify and describe clinically 
relevant subtypes of perinatal depression on the basis of RDoC symptom dimensions in the 
PACT Consortium dataset, and to further characterise the subtypes by time of symptom 
onset in each trimester of pregnancy and three post-partum periods (0 to <4 weeks, ≥4 to <8 
weeks, and ≥8 weeks).
Methods
Participants
Data were assembled from a subset of seven of 19 international sites in the PACT 
Consortium, which contributed anonymised clinical data. PACT’s mission, data collection, 
and aggregation are described in detail elsewhere.11,22 Participants included women with 
reported depression in the postnatal period and were recruited from several settings 
including psychiatric clinics, obstetric clinics, primary care, and community advertisements. 
Each site obtained consent from participants and approval from its institutional review board 
for data sharing. In this subset of the PACT sample, the cohort was restricted to women aged 
19–40 years with information about onset of depressive symptoms in the perinatal period 
and complete prospective data for the ten-item EPDS, which was obtained between Oct 15, 
2012, and Oct 27, 2013. The most severe EPDS rating was selected for women with 
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longitudinal PACT records. Timing of depression onset was submitted to the PACT 
Consortium either as a clinician assessed or self-reported onset depending on the site.
The EPDS is one of the most widely studied and validated instruments for assessing 
perinatal depressive symptoms.23 On the basis of distributions seen in this sample, the EPDS 
scores were categorised into four severity levels reported in the literature (no depression, 
EPDS score 0–9; mild to moderate, 10–16; moderate to severe, 17–21; and very severe, 22–
30).11,24
Statistical analysis
Our analytical approach extends the first PACT study in several ways. We began with an 
examination of the dimensionality of the EPDS. Using the factor score symptom dimensions 
as quantitative traits, subtypes of women having similar symptom dimensions were 
identified. The subtypes were profiled according to demographics, pregnancy characteristics, 
perinatal complications, and previous history of a mood or anxiety disorder. This approach 
allowed identification of subtypes using EPDS symptom dimensions and not by differences 
in perinatal or demographic features. This analysis builds on the previous PACT study by 
including a crosssectional examination of the EPDS symptom dimensions with reported 
onset of symptoms across each trimester of pregnancy and three post-partum periods. We 
selected the three post-partum periods (0 to <4 weeks, ≥4 to <8 weeks, and ≥8 weeks) on the 
basis of the DSM-5 and WHO ICD-10 criteria for perinatal depression.25,26 Univariate and 
bivariate descriptive statistics described the characteristics of the overall sample and 
subtypes. All analyses were done with SAS version 9.4.
Analysis of symptom dimensionality and subtypes
Principal components and common factor analysis based on the tetrachoric correlation 
matrix were used to identify symptom dimensions in the EPDS. The RDoC functional 
constructs of negative valence and arousal were applied to the EPDS dimensions that aligned 
with the symptom dimensions of interest—states of depressed mood, anhedonia, and 
anxiety. Quantitative scores were assigned to each study participant on each of the three 
dimensions. These scores were subsequently used to identify subtypes of women with 
similar patterns on the three dimensions by k-means clustering. A five subtype solution met 
the statistical criterion of the cubic clustering criterion (CCC),27 which applies an algorithm 
(examples include k-means and Wards) to minimise the within-cluster sum of squares and 
squared Euclidean distances. These five subtypes aligned with clinically relevant phenotypes 
observed in post-partum depression. The subtypes were described with descriptive statistics 
and ANOVA with post-hoc Scheffe comparison of means to identify which pairs of subtypes 
were significantly different. The Scheffe is a statistical method applied after an ANOVA to 
identify which groups are significantly different when more than two groups are being 
tested. Additional details of these methods are described in the appendix.
Classification algorithms
Scoring algorithms for the three symptom dimensions and subtype membership (logistic 
regression probability of membership in each subtype) were developed to allow for 
replication in other samples. Additional details of the analyses and algorithms are presented 
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in the appendix, enabling researchers and clinicians using the EPDS to examine the 
usefulness of this approach in their unique settings.
Results
Data for 663 women (mean age 32 years [SD 4.5]) who met the study inclusion criteria were 
included in these analyses (figure 1). All data were from seven of the 19 sites. 11 of the 13 
demographic and perinatal characteristics reported in table 1 had 70% or more data 
available. The proportion of missing data ranged from 2% for marital status to 49% for the 
birth complication of pre-eclampsia. The median EPDS measurement used in these analyses 
was done 4·5 months post partum (median 135 days [IQR 51–215]). At the time of EPDS 
assessment, 167 (25%) women reported having no depressive symptoms (EPDS 0–9), 142 
(21%) reported mild to moderate symptoms (EPDS 10–16), 299 (45%) reported moderate to 
severe symptoms (EPDS 17–21), and 54 (8%) had very severe symptoms (EPDS 22–30).
We identified five subtypes of perinatal depression that differed in severity and type of 
symptoms. These subtypes are described by the onset of symptoms spanning across the 
pregnancy trimesters and early versus later post-partum periods. Ethnicity, education level, 
marital status, and medical and pregnancy complications contributed to distinguishing the 
subtypes (table 1).
The timing of onset of depressive symptoms during the perinatal period was associated with 
EPDS score. 68% of women with first trimester onset had ongoing moderate to severe or 
very severe symptoms at the time of EPDS assessment (figure 2). However, 95 (50%) of 190 
women with third trimester onset had remitted completely by that time. Later onset of 
depressive symptoms during pregnancy was associated with a better outcome at the post-
partum EPDS assessment. Women with onset of depression in the second or third trimesters 
were more likely to be in the mild to moderate category or none category at assessment 
(50% of women with onset in the second trimester and 70% with onset in the third trimester) 
compared with women with onset in the first trimester (32%). Onset of symptoms of 
depression in the post-partum period was associated with more severe depression. More than 
20% of women with post-partum depression who reported onset within the first 8 weeks post 
partum had very severe symptoms at assessment; this proportion is nearly four times higher 
than that for women who had onset of depression during pregnancy (figure 2).
The three symptom dimensions of depressed mood, anxiety, and anhedonia on the basis of 
EPDS items are presented in table 2. The three symptom dimensions identified five subtypes 
of women by use of k-means clustering on the quantitative scores. The subtypes differed on 
symptom dimensions by type of depression and severity of illness. The five subtypes are 
labelled 1 to 5 (table 3). Subtype 1 is characterised as severe anxious depression and subtype 
2 as moderate anxious depression. These two subtypes shared anxious depression symptoms 
of comorbid anxiety yet differed in severity of depression and of anxiety. Subtypes 3 and 4 
are broadly characterised as anhedonia. Subtype 3 was defined as anxious anhedonia and 
subtype 4 was defined as pure anhedonia. Women with subtype 5, resolved depression, 
reported onset of symptoms during the perinatal period, which had resolved at the time of 
EPDS assessment. In our sample, half the women had either the severe (211 [32%]) or 
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moderate (123 [19%]) anxious depression subtypes. 175 (26%) participants had the subtype 
of resolved depression, 79 (12%) had anxious anhedonia, and 75 (11%) had pure anhedonia.
Severe anxious depression (subtype 1) has significantly higher depressed mood and anxiety 
ratings compared with all the other subtypes (2, 3, 4, and 5), but does not have higher scores 
than any subtype on the anhedonia symptom dimension (table 3). Similarly, women with 
resolved depression (subtype 5) have significantly lower ratings than all other subtypes for 
all of the dimensions, apart from higher scores on the anhedonia factor than the severe 
anxious depression subtype.
Table 4 shows the distribution of EPDS scores in each subtype with overall EPDS means, 
the proportion of each subtype across the severity categories, and the mean anxiety subscale 
scores. Notably, 98% of the severe anxious depression subtypes are in the moderate to severe 
or very severe EPDS categories. The anxious anhedonia subtype has the highest proportion 
of women in the very severe EPDS category. The final item in the EPDS assesses thoughts 
of self-injury. Such thoughts are prominent in the subtypes with comorbid anxiety, and to a 
lesser extent in the pure anhedonia subtype. Both of the subtypes characterised with anxiety 
symptoms (severe anxious depression and anxious anhedonia) have higher scores on the 
EPDS anxiety subscale.28
The severe anxious depression subtype is more likely to have depression onset in the first 
trimester or more than 8 weeks after birth than during the other perinatal periods (figure 3). 
A similar pattern is seen in women characterised by the subtype moderate anxious 
depression. Women with the subtype of anxious anhedonia were more likely to have onset of 
illness during the first (0 to <4 weeks; 61%) and second (≥4 to < 8 weeks; 38%) post-partum 
periods than during the other perinatal periods; few women with this subtype had onset in 
the periods during pregnancy. Few women characterised by pure anhedonia have onset of 
illness during the immediate post-partum period (0 to <4 weeks), but they are fairly evenly 
represented across the other perinatal periods we examined. Women with resolved 
depression subtype reported onset of depression predominantly in the third trimester of 
pregnancy and not in the post-partum periods.
Discussion
We sought to empirically identify and describe clinically relevant subtypes of perinatal 
depression in a subset of the PACT Consortium dataset, and further characterise these 
subtypes by time of symptom onset within each of the three trimesters of pregnancy and 
three post-partum periods. Our study extends previous work11 by including an examination 
of onset and quality of depression symptoms during several perinatal periods. By use of a 
framework derived from the RDoC principles, we described three underlying symptom 
constructs or dimensions in the EPDS: depressed mood, anxiety, and anhedonia.
The subtypes that emerged from clustering women on patterns of factor scores were anxious 
depression, both severe and moderate, and anhedonia, alone and in combination with 
anxiety. We also found a subtype of women whose depression started in the second or third 
trimester of pregnancy and had resolved at the time of EPDS measurement. Women with the 
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subtype anxious anhedonia were more likely to have onset of illness during the first and 
second post-partum periods than during the other perinatal periods. Onset in the first 
trimester occurred for many of the women with the subtype of anxious depression. Some of 
these women might have had depression before pregnancy. Additionally, our results suggest 
that comorbid anxiety and anhedonia are prominent symptoms associated with both 
pregnancy and obstetric complications and, in a subgroup of women, onset of depression.
We also noted that onset of symptoms in the first 8 weeks of the post-partum period was 
associated with more severe depression, characterised as subtype anxious anhedonia. 
Moreover, 20% of women were still categorised as very severe at the post-partum EPDS 
assessment; an increase of almost four times compared with women who had onset of 
depression during pregnancy. In view of the enormous hormonal fluctuations that occur in 
the transition from pregnancy to post partum,14 it is reasonable to speculate that there could 
be important conceptual and biological differences underlying the severity and 
phenomenology of depression between women with onset of symptoms during pregnancy 
versus women with post-partum onset. Furthermore, there is a growing literature on the 
important role of reproductive hormones in modulating neural circuits and biological 
systems implicated in depression, suggesting that the characteristic hormone instability of 
the perinatal period could contribute to mood dysregulation in post-partum depression.14,29
Our study has several limitations. First, this is a secondary analysis of existing data; the 
sample includes seven of 19 sites in PACT and is a subset of the full PACT Consortium. The 
analysis was restricted to seven sites able to answer the time of onset question spanning the 
prenatal and post-partum period. PACT was originally created by aggregating extant data 
across international independent sites with various protocols to examine the phenotypic 
heterogeneity of post-partum depression. These protocols had inherent differences, including 
selection criteria, recruitment settings, and variables collected. Missing data occurred in two 
ways: (1) extraction from the PACT parent larger dataset created a subset for which the data 
were not missing at random since they were not collected at the site level (ie, when time of 
reported onset or complete ten-item EPDS prospective data were not available for a 
particular site, though this was not the case for the seven sites included in the analysis); and 
(2) data were missing at random within the seven sites for demographic and perinatal 
characteristics because they were not collected or available to PACT at the time of the 
analyses. This additional layer of missing data might further bias results and the 
characteristics are only presented as numbers and percentages. Therefore, missing data could 
contribute to ascertainment bias, which is an inherent concern when pooling data, and could 
potentially influence the robustness of the findings. Second, the EPDS ratings occurred 4.5 
months post partum and thus are a cross-sectional examination rather than a longitudinal 
assessment. Third, study protocols had interstudy differences including ascertainment 
criteria, recruitment settings, and the variables collected. Such differences and missing 
sociodemographic data could contribute to bias and question the strength of the results. 
Fourth, most of the data are from white women and different ethnicities might have different 
illness patterns; we also cannot exclude the role of socioeconomic status and country of 
origin on our findings, thereby potentially limiting generalisability.22 Fifth, the analyses 
were limited to variables collected across studies, and onset of depression included both 
clinical and self-report assessments. Sixth, other attributes relevant to identifying and 
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characterising subtypes of perinatal depression could exist. Few data were available for 
history of stressful life events, such as abuse or trauma, which could have a role in perinatal 
depression. Finally, we do not have detailed information about the pre-pregnancy depression 
status of the women in the dataset. Women who reported first trimester onset of symptoms 
and continued to be symptomatic over time might be more chronically depressed and might 
have had depressive symptoms before pregnancy.
However, we believe that the strengths of the results outweigh the limitations as an 
important hypothesis-generating foundation for future work. The strengths of this study 
include the novel approach to further examine subtypes of post-partum depression from a 
subset of the PACT Consortium with diverse characteristics for sites and countries and 
detailed symptom assessment using standardised measures. Validation of our findings is 
important, including the factor structure, subtypes, and associations with onset period.
In conclusion, we applied three underlying symptom dimensions measured by the EPDS that 
correlate with the RDoC framework to further examine perinatal depression, and identified 
five distinct subtypes with clear differences in time of depression onset in the perinatal 
period. Anxiety and anhedonia emerged as prominent symptom dimensions with post-
partum onset and were notably severe. Women with post-partum onset of symptoms had 
severe and persistent symptoms. Women with onset in their first trimester also remained 
highly symptomatic in the post-partum period. Therefore, to deliver the most effective 
treatment, future clinical and research efforts should focus on the potential 
phenomenological and biological differences characterising onset of depression during 
pregnancy versus the post-partum period by use of prospective and longitudinal approaches. 
The recent development of guidelines in many countries on screening and treatment for 
perinatal depression provides a strong mandate to improve mental health care for all 
perinatal women. Consequently, development of effective screening strategies across a range 
of global settings that allow for the delivery of targeted therapies to women with different 
clinical phenotypes and severity of perinatal depression is imperative. These strategies must 
address the complexities associated with differences in time of symptom onset during the 
perinatal period and the diverse symptom constructs including anxiety, low mood, and 
anhedonia.
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Research in context
Evidence before this study
We did two comprehensive searches to identify all relevant articles. First, we searched 
PubMed with the keywords “perinatal depression”, “postpartum depression”, “time of 
onset”, “pregnancy”, and “phenotypes” from inception until Feb 6, 2017. We did not 
restrict by year of publication and included all published articles. Next, we searched 
PsycInfo with the same keywords. The search yielded 38 articles from PubMed and four 
additional articles from PsycInfo that were applicable to our study objective. Previous 
work in this area is scant and few studies have examined the differences between women 
who develop depression during pregnancy compared with women who develop 
symptoms in the post-partum period. Furthermore, previous studies are limited by either 
very small sample sizes or inadequate phenotyping by time of symptom onset. Overall, 
research that investigates symptom constructs that may differentiate meaningful 
differences between depression during pregnancy versus post partum is rare, and no 
previous studies have examined the time of symptom onset in each trimester of 
pregnancy and three post-partum periods (0 to <4 weeks, ≥4 to <8 weeks, and ≥8 weeks) 
in relation to specific symptom dimensions that are based on a framework to understand 
the underlying pathophysiology.
Added value of this study
The Postpartum Depression: Action Towards Causes and Treatment (PACT) Consortium 
includes anonymised data from 19 international sites. We used data from seven of these 
sites to examine the time of onset of symptoms in the perinatal period. We examined 
National Institute of Mental Health research domain criteria (RDoC) functional 
constructs (ie, negative valence and arousal or regulatory systems) on the basis of patient 
report of symptoms assessed with the Edinburgh postnatal depression scale (EPDS) in the 
PACT Consortium. We found evidence for three underlying dimensions of depressed 
mood, anxiety, and anhedonia in perinatal depression. On the basis of these dimensions, 
we identified five distinct subtypes of perinatal depression that had clear differences in 
symptom quality and time of onset. Anxiety and anhedonia emerged as prominent 
symptom dimensions with post-partum onset and were notably severe. Our findings have 
important public health implications to address the morbidity and mortality associated 
with perinatal depression. First, clinicians should be aware that different types and 
severity of perinatal depression exist, with varying time of onset throughout pregnancy 
and post partum. Second, we identified five distinct subtypes of perinatal depression and 
found clear differences related to time of depression onset in the perinatal period.
Implications of all the available evidence
There is growing evidence that a one-size-fits-all approach can no longer be applied to 
adequately meet the mental health needs of women with perinatal psychiatric illness. 
Different types and severities of perinatal depression exist. Further research into tailoring 
treatment on the basis of subtype to improve outcomes for women with different 
phenotypes and severity of perinatal depression is needed.
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Figure 1. Participant selection
EPDS=Edinburgh postnatal depression scale. PACT=Postpartum Depression: Action 
Towards Causes and Treatment Consortium. The perinatal depression period includes each 
trimester of pregnancy and three post-partum periods (0 to <4 weeks, ≥4 to <8 weeks, and 
≥8 weeks).
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Figure 2. Edinburgh postnatal depression scale score by time of onset of perinatal depressive 
symptoms
Column data are n (%).
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Figure 3. Subtype distribution in the three trimesters of pregnancy and three post-partum 
periods
Column data are n (%). A bar representing the total sample is included on the right for 
comparison purposes. If there was no difference by onset period, each of the other bars 
would reflect the distribution of the total sample.
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Table 2
Edinburgh postnatal depression scale (EPDS) factor structure
Depressed mood Anxiety Anhedonia
Suicidal thoughts (10) 97* −17 −2
Unhappy: crying (9) 79*   19   4
Unhappy: difficulty sleeping (7) 76*   15   4
Felt sad or miserable (8) 51*   44* −2
Felt scared or panicky (5) 52*   41*   0
Anxious or worried (4)   3
  74*   1
Things on top of me (difficulty coping; 6) 11
  68* −7
Looked forward with enjoyment (2) −2     2 83*
Been able to laugh (1) −7     8 81*
Blamed myself unnecessarily (3) 13 −17 57*
EPDS item number is given in parentheses. Table entries are the standardised rotated factor loadings multiplied by 100.
*
Primary contributor to each factor.
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Table 4
Edinburgh postnatal depression scale (EPDS) categories, self-harm, and anxiety subscale in the subtypes of 
perinatal depression
Severe anxious depression
(n=211)
Moderate anxious depression
(n=123)
Anxious anhedonia
(n=79)
Pure anhedonia
(n=75)
Resolved depression
(n=175)
Total score   20.2 (1.5) 16 (2.7) 19.2 (3.8) 14.9 (3.2)     4.1 (3.0)
 None     0   0   0   4 (5%) 164 (94%)
 Mild to moderate     4 (2%) 63 (51%) 19 (24%) 45 (60%)   11 (6%)
 Moderate to severe 176 (83%) 59 (48%) 38 (48%) 26 (35%)     0
 Very severe   31 (15%)   1 (1%) 22 (28%)   0     0
Thought of harming 
self: quite often or 
sometimes
209 (99%) 94 (76%)   3 (4%) 35 (47%)     1 (1%)
EPDS anxiety subscale*     6.0 (1.1)   4.7 (1.5)   6.5 (1.7)   4.2 (1.6)     1.9 (1.6)
Data are mean (SD) or n (%). EPDS scores grouped by none (0–9), mild to moderate (10–16), moderate to severe (17–21), and very severe (22–30).
*
EPDS anxiety subscale: EPDS items 3 (blamed myself), 4 (anxious or worried), and 5 (scared or panicky).
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